NASDAQ:CLRB Cellectar Biosciences Q1 2026 Earnings Report $3.18 +0.35 (+12.37%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$3.01 -0.17 (-5.31%) As of 05/5/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cellectar Biosciences EPS ResultsActual EPSN/AConsensus EPS -$1.89Beat/MissN/AOne Year Ago EPSN/ACellectar Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$8.00 millionBeat/MissN/AYoY Revenue GrowthN/ACellectar Biosciences Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Cellectar Biosciences Earnings HeadlinesCellectar Biosciences Reports Strong Efficacy Results for Iopofosine I 131 in Heavily Pretreated Waldenström Macroglobulinemia Patients, Supporting Accelerated Approval PathwayMay 5 at 7:30 AM | quiverquant.comQCellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström MacroglobulinemiaMay 5 at 7:10 AM | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day. | Brownstone Research (Ad)Cellectar Biosciences Announces Oversubscribed Financing Up to $140 MillionMay 5 at 7:00 AM | globenewswire.comCellectar Biosciences (NASDAQ:CLRB) Shares Pass Above Fifty Day Moving Average - Here's What HappenedMay 5 at 4:27 AM | americanbankingnews.comCellectar Biosciences (CLRB) price target decreased by 59.62% to 14.28April 28, 2026 | msn.comSee More Cellectar Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectar Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectar Biosciences and other key companies, straight to your email. Email Address About Cellectar BiosciencesCellectar Biosciences (NASDAQ:CLRB) is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy. Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma. In addition to its therapeutic pipeline, Cellectar has developed CLR 1501 and CLR 1502, fluorescent and near‐infrared imaging probes that enhance intraoperative tumor detection and surgical guidance. These imaging agents are intended to help surgeons distinguish cancerous tissue from healthy tissue in real time. Founded in 2007 and headquartered in Madison, Wisconsin, Cellectar Biosciences conducts its research and development primarily in the United States. Preclinical and clinical studies have demonstrated the selective uptake and prolonged retention of its PDC compounds in tumor cells, supporting the potential of its platform across a range of oncologic indications. The company collaborates with academic centers and contract research organizations to advance its clinical programs. Under the leadership of President and Chief Executive Officer Will Berry, Cellectar Biosciences is advancing its pipeline and engaging with regulatory agencies to support future product commercialization. The company continues to explore strategic partnerships and funding opportunities to further develop its PDC technology for both therapeutic and diagnostic applications in oncology.View Cellectar Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
